Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Annals of the Rheumatic Diseases|December 4, 2020
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2Philip J Mease, Apinya Lertratanakul, Jaclyn K Anderson, et al.
Lancet (London, England)|November 17, 2019
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trialDésirée van der Heijde, In-Ho Song, Aileen L Pangan, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|April 23, 2014
Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory SarcoidosisNadera J Sweiss, Imre Noth, Mehdi Mirsaeidi, et al.
Rheumatology and Therapy|April 29, 2021
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 StudyPhilip J Mease, Apinya Lertratanakul, Kim A Papp, et al.
The Journal of Allergy and Clinical Immunology|December 2, 2019
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trialEmma Guttman-Yassky, Diamant Thaçi, Aileen L Pangan, et al.
Lancet (London, England)|July 3, 2018
Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind studyRobert Landewé, Joachim Sieper, Philip Mease, et al.
Lancet (London, England)|May 23, 2021
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trialsEmma Guttman-Yassky, Henrique D Teixeira, Eric L Simpson, et al.
Lancet (London, England)|June 1, 2022
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trialsSilvio Danese, Séverine Vermeire, Wen Zhou, et al.
Gastroenterology|February 12, 2020
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's DiseaseWilliam J Sandborn, Brian G Feagan, Edward V Loftus, et al.
Pageof 5